With strong off-label use already, even with new warnings about the risk of developing second primary malignancies, the new approval for Celgene Corp.’s oral immunomodulator Revlimid (lenalidomide) in newly diagnosed multiple myeloma – with continuous use to disease progression – should continue growth for the company’s pivotal product.
The new indication, cleared Feb. 18, satisfies a long-standing goal for the company. Revlimid was first approved in 2006 for...
Welcome to Pink Sheet
Create an account to read this article
Already a subscriber?